Qalsody moves closer to public funding in Canada
Related topics
Qalsody (tofersen), a treatment for adults with ALS who have SOD1 gene mutations, is moving closer to public healthcare coverage in Canada. The development follows conditional approval by Health Canada, according to a report highlighted by Curalysis.
Why this matters
If funding is approved, eligible adults with SOD1 mutations could have improved access through Canada’s public healthcare system. Coverage has not yet been confirmed, so this does not establish that the treatment is currently publicly funded.
Limitations and context
This update is based on a Curalysis research-and-news roundup citing an ALS News Today report, not a primary research study or a confirmed Canadian funding decision. The source does not provide details of the funding process, eligibility rules, timing, or the evidence behind the conditional approval.